ES2169864T3 - Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis. - Google Patents

Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.

Info

Publication number
ES2169864T3
ES2169864T3 ES97926889T ES97926889T ES2169864T3 ES 2169864 T3 ES2169864 T3 ES 2169864T3 ES 97926889 T ES97926889 T ES 97926889T ES 97926889 T ES97926889 T ES 97926889T ES 2169864 T3 ES2169864 T3 ES 2169864T3
Authority
ES
Spain
Prior art keywords
endogline
monoclonal antibodies
angiogenesis
angiogenesis therapy
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97926889T
Other languages
English (en)
Inventor
Ben K Seon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of ES2169864T3 publication Critical patent/ES2169864T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN ANTICUERPO MONOCLONAL, O FRAGMENTOS DEL MISMO, QUE TIENE ESPECIFICIDAD DE UNION TANTO PARA LA ENDOGLINA EXPRESADA EN CELULAS ENDOTELIALES VASCULARES HUMANAS PROLIFERATIVAS COMO PARA LA ENDOGLINA EXPRESADA EN CELULAS ENDOTELIALES MURINAS PROLIFERATIVAS. LA TERAPIA ANTIANGIOGENICA EN MAMIFEROS PUEDE EFECTUARSE MEDIANTE LA ADMINISTRACION A UN HUESPED MAMIFERO DE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE DICHO ANTICUERPO MONOCLONAL ANTIENDOGLINA O FRAGMENTOS DEL MISMO, EL CUAL SE CONJUGA AL MENOS CON UN INHIBIDOR DE ANGIOGENESIS O AGENTE ANTITUMORAL. LA COMPOSICION ES UTIL PARA TRATAR ENFERMEDADES ASOCIADAS A LA ANGIOGENESIS Y A LOS TUMORES.
ES97926889T 1996-05-31 1997-05-30 Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis. Expired - Lifetime ES2169864T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65595396A 1996-05-31 1996-05-31

Publications (1)

Publication Number Publication Date
ES2169864T3 true ES2169864T3 (es) 2002-07-16

Family

ID=24631047

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97926889T Expired - Lifetime ES2169864T3 (es) 1996-05-31 1997-05-30 Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.

Country Status (8)

Country Link
US (2) US5928641A (es)
EP (1) EP0938505B1 (es)
JP (1) JP4318752B2 (es)
AT (1) ATE214075T1 (es)
CA (1) CA2256413C (es)
DE (1) DE69710911T2 (es)
ES (1) ES2169864T3 (es)
WO (1) WO1997045450A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
JP4531267B2 (ja) * 1999-01-22 2010-08-25 ザ バーナム インスティチュート ホーミングプロアポトーシス結合体およびホーミングプロアポトーシス結合体を使用する方法
US7125542B2 (en) * 2000-02-10 2006-10-24 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
DE10043481A1 (de) * 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
JP2003021631A (ja) * 2001-05-10 2003-01-24 Chugai Pharmaceut Co Ltd 骨転移抑制剤のスクリーニング方法
US20030129193A1 (en) * 2001-09-27 2003-07-10 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coaguligand treatment
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AP2740A (en) * 2003-08-01 2013-09-30 Genentech Inc Anti-VEGF antibodies
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
KR20130119506A (ko) 2004-09-24 2013-10-31 베스 이스라엘 데코니스 메디칼 센터 임신성 합병증의 진단 및 치료 방법
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
WO2007053161A2 (en) * 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
BRPI0717964A2 (pt) 2006-11-02 2013-12-17 Acceleron Pharma Inc Receptor e antagonistas de ligante da alk1 e usos dos mesmos.
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
KR20180029111A (ko) 2008-05-02 2018-03-19 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2657497T3 (es) 2009-08-17 2018-03-05 Tracon Pharmaceuticals, Inc. Terapia de combinación de cáncer con anticuerpos antiendoglina y agentes anti-VEGF
ES2632748T3 (es) * 2009-12-09 2017-09-15 Bayer Pharma Aktiengesellschaft Anticuerpos anti-C4.4a y usos de los mismos
CA2827952A1 (en) 2011-02-23 2012-11-01 Health Research, Inc. Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2014200618A1 (en) 2013-06-14 2014-12-18 Agilent Technologies Inc. System and method for facilitating manual sorting of objects
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
TWI748962B (zh) 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
RU2607029C1 (ru) * 2015-10-20 2017-01-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ" Минздрава России ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК ЖИВОТНЫХ Mus musculus L. - EN-4C9 - ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ ПРОТИВ ЭНДОГЛИНА (CD105) ЧЕЛОВЕКА
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59
CN106928355B (zh) * 2015-12-30 2020-09-29 广西医科大学 一种CD105纳米抗体Nb184
WO2017223495A1 (en) 2016-06-24 2017-12-28 University Of South Carolina Inhibin as targetable regulators of angiogenesis
EP3900733A1 (en) 2020-04-24 2021-10-27 Derma Innovate S.L. Src kinase activators and eng function inhibitors as enhancers of skin homeostasis/regeneration and hair growth
CN115991773B (zh) * 2022-08-15 2023-11-17 营龄(武汉)生物科技有限公司 一种含有人血白蛋白的药物组合物
CN116063496B (zh) * 2022-08-15 2023-10-24 营龄(武汉)生物科技有限公司 载药的人血白蛋白联合单克隆抗体在制备药物组合物中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94389A0 (en) * 1989-06-01 1991-03-10 Health Research Inc Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and method of using same for diagnosis and treatment
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors

Also Published As

Publication number Publication date
WO1997045450A1 (en) 1997-12-04
US5928641A (en) 1999-07-27
JP2000511425A (ja) 2000-09-05
CA2256413C (en) 2007-07-03
ATE214075T1 (de) 2002-03-15
JP4318752B2 (ja) 2009-08-26
US6200566B1 (en) 2001-03-13
EP0938505A4 (en) 2000-07-19
DE69710911T2 (de) 2002-09-19
EP0938505B1 (en) 2002-03-06
DE69710911D1 (de) 2002-04-11
EP0938505A1 (en) 1999-09-01
CA2256413A1 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
ES2169864T3 (es) Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
DE69729283D1 (de) GLYKOSYLIERTE IgG ANTIKÖRPER
NO985150D0 (no) Antigenbindende fragment som sµrlig sporer kreftceller, nukleoid som koder nevnte fragment, samt bruk av dette ved forebygging og pÕvisning av kreft
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
NO974943L (no) Angiostatinfragmenter, aggregert angiostatin og anvendelse derav
WO1994004702A3 (en) Improved detection and therapy of lesions with biotin/avidin conjugates
DK79390A (da) Anti-leukocytkonjugat og anvendelse heraf
DE3888224D1 (de) Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
NO20005155D0 (no) Forbedring av antistoff-cytokin fusjonsprotein medierte immunresponser ved ko-administrering med angiogenese inhibitor
EP1245676A4 (en) HUMANE MONOCLONAL ANTIBODIES AGAINST THE TGF-BETA II RECEPTOR AND THEIR MEDICAL USE
ES2120948T3 (es) Procedimiento y composiciones que mejoran los sintomas de la sepsis.
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
CA2364026A1 (en) Anti-tnf.alpha. antibodies in therapy of asthma
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
WO1999002545A3 (en) Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
DE69125855T2 (de) Therapeutisch wirksame, örtliche anwendung von st1435
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
ATE97324T1 (de) Verwendung von amphipatischen molekuelen zur radiodarstellung und therapie mittels monoklonaler oder polyklonaler antikoerperkonjugate.
WO2001091792A3 (en) Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network
BR9807980A (pt) Uso de um composto e composto para tratar um mamìfero com disfunção cognitiva

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 938505

Country of ref document: ES